Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Diet and lifestyle. The original article is from msn.com.

Cure8 found this source from onlinelibrary.wiley.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Procedures and surgery. Open the original article for the full details.

People with both psoriasis and hidradenitis suppurativa appear to have higher overall morbidity and a greater observed risk of Crohn’s disease. Genetic findings suggest shared biological pathways that could affect how...

Cure8 could only read part of this source from ajmc.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease and Access, cost, and policy.

This reports a potential new way to extend remission after exclusive enteral nutrition by combining diet with fecal microbiome transfer—an approach that targets the gut microbiome rather than adding drugs. If effective,...

This story matters because it outlines a plausible way to extend the benefits of exclusive enteral nutrition (EEN) for Crohn's disease by using fecal microbiome transfer (FMT) to 'lock in' a healthier microbiome and...

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Access, cost, and policy. Open the original article for the full details.

This study tests whether a ‘microbiome reboot’ — using exclusive enteral nutrition followed by fecal microbiome transfer — can make the beneficial microbiome changes last longer and help keep Crohn’s disease in...

Cure8 could only read part of this source from eurekalert.org, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical...

This study tests whether combining exclusive enteral nutrition with a follow-up fecal microbiome transfer can create a longer-lasting, less inflammatory gut microbiome — which could help maintain remission in Crohn’s...

Access and insurance issues can delay IBD medications and lead patients to skip doses or make financial sacrifices. That can worsen health and daily life, so this affects many people with Crohn’s disease and ulcerative...

Longer-term (two-year) results suggest mirikizumab (Omvoh) can maintain clinical and endoscopic benefits for many people with Crohn’s disease, including some with prior biologic failure, which is important when weighing...

Personal stories like Amy Dowden’s can offer encouragement and visibility for people living with Crohn’s disease and those facing cancer, showing challenges around treatment, body image, and recovery. It highlights...

Cure8 could only read part of this source from thechronicle.com.au, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease and Diet and lifestyle.

This suggests an existing antibiotic, vancomycin, may help a specific group of IBD patients who also have primary sclerosing cholangitis (PSC), including some who did not respond to other IBD treatments. If confirmed in...

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Anti-TNF. The original article is from msn.com.

This study suggests a common genetic marker (HLA‑DQA1*05) may help explain why some children stop responding to anti‑TNF drugs and could eventually guide who might benefit from adding methotrexate or closer monitoring.

Cure8 could only read part of this source from theaustralian.com.au, so this card uses cautious topic tags instead of a full summary. It is tagged for Community and awareness.

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Medications. Open the original article for the full details.

Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.

A public figure with Crohn’s disease is the subject of a high-profile estate dispute; mentions of his long battle with Crohn’s may be of interest to people who follow celebrities living with IBD or who seek solidarity in...

People with IBD who need advanced therapies may worry about cardiovascular risks linked to some JAK inhibitors. This study suggests, in a real-world cohort with cardiovascular risk factors, short-term (1-year) MACE risk...

Understanding that low patient activation can reflect poor health literacy helps explain disparities in access, diagnosis delays, and outcomes for children with IBD. Improving communication and education could make care...

Long-term maintenance of clinical and endoscopic remission is a key goal in Crohn’s disease care. Positive two-year data and FDA approval may affect treatment options for adults, including people who previously failed...

These are multi‑year clinical results for a newly approved IL‑23p19 inhibitor (mirikizumab) showing sustained clinical and endoscopic benefit for many patients with moderate‑to‑severe Crohn’s disease, including some who...

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Medications. Open the original article for the full details.

Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Ustekinumab. The original article is from msn.com.

Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from msn.com.

A noninvasive wearable that tracks inflammation markers could let people with IBD and their clinicians detect rising disease activity earlier and potentially act before symptoms develop. This may make monitoring less...

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Risankizumab, IL-23 inhibitor, and Medications. Open the original article for the full details.

Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease and Medications. The original article is from geneonline.com.

Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

Vulvar Crohn’s is an uncommon but real extraintestinal manifestation that can cause painful skin changes and sometimes appears before GI Crohn’s is diagnosed. Knowing about it may speed diagnosis and lead to coordinated...

Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from firstwordpharma.com.

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Diet and lifestyle. Open the original article for the full...

The article centers on how Crohn’s affects Black people differently because of access barriers, stigma, and underrepresentation—issues that can influence diagnosis, disease severity, and quality of life.

Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.

Long-term data matter because they show whether benefits and safety of a new biologic hold up beyond the initial trial period. For people with Crohn’s disease, sustained clinical remission and endoscopic healing are...

Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

Durable treatment responses matter to people with Crohn’s disease because sustained clinical remission and endoscopic improvement can mean fewer symptoms and less inflammation over time. Longer safety and durability data...

This article reports two-year data showing that mirikizumab (Omvoh) maintained clinical and endoscopic benefit for many people with moderate–severe Crohn’s disease, and that results across Phase 3 programs also support...

Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

This press release reports multi-year data suggesting many patients treated continuously with mirikizumab maintained clinical remission and endoscopic response at two years—outcomes people with Crohn’s disease often care...

A new VEGFR2-targeted ultrasound contrast (BR55) has FDA fast track status for imaging active Crohn’s inflammation, which could eventually offer a non‑invasive way to monitor disease activity and treatment response...

Long-term results matter because they report whether an IL‑23 inhibitor (Omvoh) maintained clinical and endoscopic improvements through two years for people with moderate-to-severe Crohn’s disease, including some with...

This agent is being developed as a targeted, radiation-free ultrasound contrast to detect active bowel inflammation and angiogenesis in Crohn’s disease, which could improve non-invasive monitoring of disease activity and...

This press release reports multi-year clinical trial data suggesting sustained remission and intestinal healing with Omvoh (mirikizumab) in patients with Crohn's disease—information that could affect treatment...

This roundup highlights new IBD research and real-world care issues that could influence future diagnosis, monitoring, and access to treatments. Findings on financial barriers and gaps in treat-to-target monitoring may...